Skip to main content
Veterinary Medicines

CANIVERM mite, Tableta

Authorised
  • Pyrantel embonate
  • Praziquantel
  • Fenbendazole

Product identification

Medicine name:
CANIVERM mite, Tableta
Active substance:
  • Pyrantel embonate
  • Praziquantel
  • Fenbendazole
Target species:
  • Dog
  • Other Canids
  • Cat
  • Other Felids
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Pyrantel embonate
    36.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    12.50
    milligram(s)
    /
    1.00
    Tablet
  • Fenbendazole
    37.50
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Other Canids
    • Cat
    • Other Felids
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC30
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicines
Authorisation number:
  • 96/025/01-C
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."